Pridopidine

Drug Profile

Pridopidine

Alternative Names: ACR-16; ASP 2314; FR-310826; Huntexil; TV-7820

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator NeuroSearch Sweden AB
  • Developer NeuroSearch Sweden AB; Teva Pharmaceutical Industries
  • Class Antiparkinsonians; Antipsychotics; Neuropsychotherapeutics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Glutamate modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Huntington's disease
  • Discontinued Parkinson's disease; Schizophrenia

Most Recent Events

  • 11 Jan 2017 Teva Branded Pharmaceutical Products, R&D plans a phase I trial for Huntington’s disease in USA (PO, Capsule)(NCT03019289)
  • 19 Sep 2016 Interim adverse events and efficacy data from phase II Pride-HD trial in Huntington's disease released by Teva
  • 09 Sep 2015 Prilopidine is still in phase-II/III development for Huntington's disease in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top